Biotec Pharmacon ASA (OSE: BIOTEC) has been granted patent in the US for the technology platform of gel forming Soluble Beta-Glucan (SBG).
The granted patent US 9,623,043 title of invention: Glucan. The claims cover the method for producing a gel forming SBG and the product obtainable by this method as well as the medical use of the glucan gel. The patent is valid to 2031
“We are very pleased with this patent as it secures our intellectual property in the important US market for the technology platform of Woulgan. It will be important in the market development not least in the partner discussions as it gives a potential partner security that any investments made is being protected”, says Svein Lien, CEO, Biotec Pharmacon ASA